TTD | Drug: D0T0VC

Drug General Information
Drug ID	D0T0VC
Former ID	DNC006826
Drug Name	5-phenylamino-4-cyano-3-hydroxy-isothiazole
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[528219]
Formula	C10H7N3OS
Canonical SMILES	C1=CC=C(C=C1)NC2=C(C(=O)NS2)C#N
InChI	1S/C10H7N3OS/c11-6-8-9(14)13-15-10(8)12-7-4-2-1-3-5-7/h1-5,12H,(H,13,14)
InChIKey	GHXPCAXQBVCFNU-UHFFFAOYSA-N
PubChem Compound ID	2726555
Target and Pathway
Target(s)	Dual specificity mitogen-activated protein kinase kinase 1	Target Info	Inhibitor	[528219]
KEGG Pathway	MAPK signaling pathway
	ErbB signaling pathway
	Ras signaling pathway
	Rap1 signaling pathway
	cGMP-PKG signaling pathway
	cAMP signaling pathway
	Chemokine signaling pathway
	HIF-1 signaling pathway
	FoxO signaling pathway
	Sphingolipid signaling pathway
	Oocyte meiosis
	PI3K-Akt signaling pathway
	Vascular smooth muscle contraction
	Dorso-ventral axis formation
	VEGF signaling pathway
	Osteoclast differentiation
	Focal adhesion
	Gap junction
	Signaling pathways regulating pluripotency of stem cells
	Toll-like receptor signaling pathway
	Natural killer cell mediated cytotoxicity
	T cell receptor signaling pathway
	B cell receptor signaling pathway
	Fc epsilon RI signaling pathway
	Fc gamma R-mediated phagocytosis
	TNF signaling pathway
	Long-term potentiation
	Neurotrophin signaling pathway
	Cholinergic synapse
	Serotonergic synapse
	Long-term depression
	Regulation of actin cytoskeleton
	Insulin signaling pathway
	GnRH signaling pathway
	Progesterone-mediated oocyte maturation
	Estrogen signaling pathway
	Melanogenesis
	Prolactin signaling pathway
	Thyroid hormone signaling pathway
	Oxytocin signaling pathway
	Prion diseases
	Alcoholism
	Hepatitis B
	Influenza A
	Pathways in cancer
	Proteoglycans in cancer
	MicroRNAs in cancer
	Colorectal cancer
	Renal cell carcinoma
	Pancreatic cancer
	Endometrial cancer
	Glioma
	Prostate cancer
	Thyroid cancer
	Melanoma
	Bladder cancer
	Chronic myeloid leukemia
	Acute myeloid leukemia
	Non-small cell lung cancer
	Central carbon metabolism in cancer
	Choline metabolism in cancer
NetPath Pathway	FSH Signaling Pathway
NetPath Pathway	TGF_beta_Receptor Signaling Pathway
PANTHER Pathway	Angiogenesis
	B cell activation
	EGF receptor signaling pathway
	Endothelin signaling pathway
	FGF signaling pathway
	Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
	Integrin signalling pathway
	PDGF signaling pathway
	T cell activation
	Toll receptor signaling pathway
	VEGF signaling pathway
	Ras Pathway
	Angiotensin II-stimulated signaling through G proteins and beta-arrestin
	CCKR signaling map ST
Pathway Interaction Database	Fc-epsilon receptor I signaling in mast cells
	Endothelins
	BCR signaling pathway
	GMCSF-mediated signaling events
	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
	EPHB forward signaling
	SHP2 signaling
	Netrin-mediated signaling events
	mTOR signaling pathway
	Class IB PI3K non-lipid kinase events
	IL2-mediated signaling events
	Ras signaling in the CD4+ TCR pathway
	Ceramide signaling pathway
	IFN-gamma pathway
	ErbB1 downstream signaling
	ErbB2/ErbB3 signaling events
	FOXM1 transcription factor network
	PDGFR-beta signaling pathway
	Neurotrophic factor-mediated Trk receptor signaling
	Nongenotropic Androgen signaling
	Hedgehog signaling events mediated by Gli proteins
	CXCR3-mediated signaling events
	Signaling events mediated by Stem cell factor receptor (c-Kit)
	Signaling events mediated by VEGFR1 and VEGFR2
	Cellular roles of Anthrax toxin
	Trk receptor signaling mediated by the MAPK pathway
	Downstream signaling in na&#xef
	Signaling events mediated by focal adhesion kinase
PathWhiz Pathway	Fc Epsilon Receptor I Signaling in Mast Cells
PathWhiz Pathway	Insulin Signalling
Reactome	MAPK3 (ERK1) activation
	Uptake and function of anthrax toxins
	RAF activation
	MAP2K and MAPK activation
	Negative feedback regulation of MAPK pathway
	MAP3K8 (TPL2)-dependent MAPK1/3 activation
WikiPathways	Toll-like receptor signaling pathway
	Serotonin Receptor 4/6/7 and NR3C Signaling
	Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
	Serotonin HTR1 Group and FOS Pathway
	Estrogen signaling pathway
	TCR Signaling Pathway
	ErbB Signaling Pathway
	Hypothetical Network for Drug Addiction
	Senescence and Autophagy in Cancer
	EPO Receptor Signaling
	Regulation of Actin Cytoskeleton
	IL-2 Signaling Pathway
	Insulin Signaling
	EGF/EGFR Signaling Pathway
	MAPK Cascade
	MAPK Signaling Pathway
	TGF beta Signaling Pathway
	IL-6 signaling pathway
	Signaling of Hepatocyte Growth Factor Receptor
	Focal Adhesion
	Kit receptor signaling pathway
	IL-3 Signaling Pathway
	Bladder Cancer
	Cardiac Hypertrophic Response
	MAP kinase activation in TLR cascade
	RAF/MAP kinase cascade
	Nanoparticle-mediated activation of receptor signaling
	Structural Pathway of Interleukin 1 (IL-1)
	Genes and (Common) Pathways Underlying Drug Addiction
	Nifedipine Activity
	Aryl Hydrocarbon Receptor
	PDGF Pathway
	BDNF signaling pathway
	Integrated Pancreatic Cancer Pathway
	Oncostatin M Signaling Pathway
	Corticotropin-releasing hormone
	Interleukin-11 Signaling Pathway
	AGE/RAGE pathway
	B Cell Receptor Signaling Pathway
	Prostate Cancer
	Signaling Pathways in Glioblastoma
	TSLP Signaling Pathway
	IL-9 Signaling Pathway
	Endothelin Pathways
	IL-7 Signaling Pathway
	Leptin signaling pathway
	TSH signaling pathway
	RANKL/RANK Signaling Pathway
	IL-1 signaling pathway
	Signaling by FGFR
	Integrin-mediated Cell Adhesion
	L1CAM interactions
	MicroRNAs in cardiomyocyte hypertrophy
	Regulation of toll-like receptor signaling pathway
	Osteopontin Signaling
	IL-5 Signaling Pathway
References
Ref 528219	Bioorg Med Chem Lett. 2006 Aug 1;16(15):3975-80. Epub 2006 May 24.Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors.
Ref 528219	Bioorg Med Chem Lett. 2006 Aug 1;16(15):3975-80. Epub 2006 May 24.Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors.

Drug Information